Abstract
Abstract 21
Background: There is evidence of under-detection and poor management of pain in patient with 22 dementia, in both long-term and acute care. Accurate assessment of pain in people with dementia is 23 challenging and pain assessment tools have received considerable attention over the years, with an 24 increasing number of tools made available. Systematic reviews on the evidence of their validity and 25 utility mostly compare different sets of tools. This review of systematic reviews analyses and 26 summarises evidence concerning the psychometric properties and clinical utility of pain assessment 27 tools in adults with dementia or cognitive impairment. 28
Methods:
We searched for systematic reviews of pain assessment tools providing evidence of 29 reliability, validity and clinical utility. Two reviewers independently assessed each review and 30 extracted data from them, with a third reviewer mediating when consensus was not reached. 31
Analysis of the data was carried out collaboratively. The reviews were synthesised using a narrative 32 synthesis approach. 33
Results:
We retrieved 441 potentially eligible reviews, 23 met the criteria for inclusion and 8 34 provided data for extraction. Each review evaluated between 8 and 13 tools, in aggregate providing 35 evidence on a total of 28 tools. The quality of the reviews varied and the reporting often lacked 36 sufficient methodological detail for quality assessment. The 28 tools appear to have been studied in 37 a variety of settings and with varied types of patients. The reviews identified several methodological 38 limitations across the original studies. The lack of a 'gold standard' significantly hinders the 39 evaluation of tools' validity. Most importantly, the samples were small providing limited evidence for 40 use of any of the tools across settings or populations. 41
Conclusions:
There are a considerable number of pain assessment tools available for use with the 42 elderly cognitive impaired population. However there is limited evidence about their reliability, 43 validity and clinical utility. On the basis of this review no one tool can be recommended on the basis 44 of the existing evidence. 45
Background

48
Dementia affects an estimated 44.4 million people worldwide -a figure which is set to rise -and 49
represents an important public health issue, costing an estimated US$604 billion each year [1] . 50
Dementia presents a particular challenge for treatment and care due to the progressive cognitive 51 and functional decline that are hallmarks of the condition. In particular, loss of language and the 52 ability to communicate raises the risk of unmet need. A critical example of this issue is in the 53 assessment of pain. 54
Pain is common in older adults, with up to one third of community-dwelling people over 60 55 experiencing regular pain and 50% of people over 80 regularly taking analgesics [2] . Although pain in 56 dementia is difficult to assess, the literature agrees that at least 50% of people with dementia also 57 regularly experience pain [3] , which is predominantly, but not exclusively related to the 58 musculoskeletal system. Osteoarthritis is very common in these individuals [4] , and pain is also 59 frequently caused by falls, pressure ulcers, infections and underlying neuropathy due to 60 comorbidities [5] . 61
In addition to significant distress and discomfort, untreated pain can also be a causative factor in key 62 symptoms and quality of life indicators for people with dementia. Behavioural and psychological 63 symptoms of dementia such as agitation and aggression often arise as a result of underlying pain, 64 presenting a considerable challenge for treatment and care that may lead to institutionalisation or 65 prescriptions of antipsychotic medications that carry serious safety concerns [6] . The accurate and 66 timely assessment of pain is therefore of critical importance when considering the overall care for 67 people with dementia. In general, due to the subjectivity of pain, self-report is considered to be the 68 gold standard for pain assessment. While people with mild to moderate dementia are often able to 69 report their pain verbally or use simple visual or numerical pain intensity assessment tools, these 70 with validation data pertaining to the treatment of people with dementia. This meta-review presents 97 a thorough synthesis of current systematic review literature concerning the psychometric properties 98 and clinical utility of pain assessment tools for the assessment of pain in adults with dementia. 99
Methods
100
For ease of reference, in this paper we refer to our systematic review of systematic reviews as a 101 meta-review; we call the systematic reviews considered for inclusion in the meta-review reviews and 102 refer to publications included in the reviews as studies; we use the term records to refer to the 103 bibliographic data of publications of reviews (for the most part retrieved thought online database 104 searches); the terms (pain assessment) scales, tools and instruments are used interchangeably. The 105 process of the meta-review followed guidance from The Cochrane Collaboration [15] and the 106 Joanna Briggs Institute [16] . In undertaking this meta-review, our review questions were the 107 following: 108 1) Which tools are available to assess pain in adults with dementia? 109 2) In which settings are they used and with what patient population? 110
3) What are their reliability, validity and clinical utility? 111
Criteria for considering reviews for inclusion 112
Definitions of criteria for inclusion of reviews in the meta-review followed an adapted SPICE 113 structure (Setting, Population, Intervention, Comparison, method of Evaluation) [16] (Table 1) . We 114 included reviews systematic reviews of pain assessment tools involving adults with dementia or with 115 cognitive impairment. Dementia and cognitive impairment were defined according to the US 116 National Library of Medicine Medical Subject Heading (MeSH) vocabulary. Dementia was defined as 117 "an acquired organic mental disorder with loss of intellectual abilities of sufficient severity to 118 interfere with social or occupational functioning.
[…]" [17] . The Dementia MeSH term covers more 119 specific subheadings such as Alzheimer Disease or Vascular Dementia. Cognition Disorder was 120 defined as: "Disturbances in the mental process related to thinking, reasoning, and judgment" [18] 121 (distinct from, not including, Delirium). We did not include Learning Disorders, defined as: 122 "Conditions characterized by a significant discrepancy between an individual's perceived level of 123 intellect and their ability to acquire new language and other cognitive skills.
[…]" [19] . Examples of 124 learning disorders of this type are dyslexia, dyscalculia, and dysgraphia. 125
We included reviews regardless of setting (e.g. acute, or nursing/care homes), type, location or 126 intensity of pain (e.g. acute pain, persistent), and outcomes of the pain assessment (e.g. patients 127
being in pain or not). Reviews were included if they provided psychometric data for the pain 128 assessment tools and were available in English. We excluded publications, such as narrative reviews 129 or case reports, which did not provide psychometric data or were not categorized as systematic 130 reviews [20] (see Table 1 for our systematic review definition). 131
Search methods for identification of reviews 132
The following databases were searched (details provided in Table 2 ): Medline, All EBM Reviews 133 (including Cochrane DSR, ACP Journal Club, DARE, CCTR, CMR, HTA, and NHSEED), Embase, 134
PsycINFO, and CINHAL; the searches were carried out all on the same date (12 March 2013). 135
Additional searches included the Joanna Briggs Institute (JBI) Library (The JBI Database of Systematic 136
Reviews and Implementation Reports) and the Centre for Reviews and Dissemination database. 137
Further data was retrieved through reference chaining. No grey literature was sought. 138
The search strategy used a combination of text words and established indexing terms such as 139
Medical Subject Headings (Table 3) . The search was structured by the relevant SPICE concepts. 140 Search terms were identified by comparing published search strategies adopted by reviews in similar 141 areas (such as [21, 22] ), or on the subject of pain or pain management tools, not specifically for the 142 same patient population [23], using the search strategy for retrieving reviews outlined by Montori 143 et al. [24] . Detailed search strategies were optimised for each electronic database searched (see 144
Additional file 1). 145
Selection of reviews 146
Four reviewers (DD, MB, VL, PE) screened all search results, initially on the basis of title and abstract 147 and then the full text of potentially eligible papers (Figure 1) . The results of the search were divided 148 into two sets among the reviewers, so that each review was assessed by two people independently. 149
When consensus could not be reached, the reviews were referred to a third party (SJC) (details of 150 this process available in Additional files 2-3). 151
Assessment of methodological quality of included reviews 152
The PRISMA guidance on systematic reviews explains how, in carrying out a systematic review, it is 153 important "to distinguish between quality and risk of bias and to focus on evaluating and reporting 154 the latter" [20] . The authors encourage the reviewers "to think ahead carefully about what risks of 155 bias (methodological and clinical) may have a bearing on the results of their systematic reviews" 156
[20]. In our meta-review, the risk of bias may reside in each review considered for inclusion, as well 157 as in the original studies that comprise that review. We did not access the studies to be able to 158 accurately judge their quality or risk of bias. In terms of each review, we assessed risk of bias in 159 terms of how the review was conducted and the criteria applied for inclusion/exclusion. Critical 160 appraisal was carried out by two independent reviewers, using the AMSTAR systematic review 161 critical appraisal tool [25] . Critical appraisal and evaluation of potential bias was carried out at the 162 time of data extraction, after screening was completed on the basis of the inclusion criteria. 163
Data extraction and management 164
Data were extracted by two reviewers independently using a set of data extraction forms which was 165 developed for the meta-review: 1) the AMSTAR checklist [25] , 2) two forms for data about the 166 reviews and 3) one form for data about the tools (Additional file 4). The latter included a field for 167 data extraction on the user-centredness of the tools, informed by Dixon and Long's work on the 168 development of health status instruments [26] . The data extraction forms were both paper-based 169 and built into a MS Access database. At the time of data extraction, the reviews eligible for inclusion 170 were screened further on the basis of availability of psychometric data of tools. At this point, we 171 found that some of the reviews initially identified as being eligible for inclusion in the meta-review 172 did not provide psychometric data of tools and were subsequently excluded (this is discussed in 173 detail in the results section). Data about the characteristics of the tool (e.g. tool design and 174 instructions for use) were extracted from the reviews; we did not search for, nor retrieve, the 175 original tools. The reviews were synthesised using a narrative synthesis approach. 176
Results and discussion
177
The search retrieved 441 potentially eligible unique records. After screening titles and abstracts, and 178 further removing duplicates, we obtained the full text of 183 records and assessed these for 179 eligibility. We identified 23 reviews as being potentially eligible for inclusion, of which 13 were 180 excluded as they did not provide data on the psychometric properties of the tools. The remaining set 181 included 10 records reporting data from eight reviews (Schofield et al. 2005 [27] review was 182 reported in three separate studies [27-29], we have combined the results of this) (Figure 2 ). Table 4  183 provides details of the eight included reviews and Table 5 details of the 13 excluded reviews. 184
The findings are structured as follows. First, we briefly summarise the reviews considered at the time 185 of data extraction but excluded for lack of data on psychometric properties of the tools. We then 186 describe the reviews included in our analysis -their methods and our quality assessment. Third, we 187 describe the findings of these reviews, i.e. the pain assessment tools -characteristics, psychometric 188 properties, feasibility of use and clinical utility. We conclude with the reviews' overall assessment of 189 these tools. 190
Description of excluded reviews 191
Thirteen of the 23 reviews were excluded because they did not provide suitable data for extraction 192 (these data were absent or not reported in a format suitable for extraction). Several of these were 193 narrative reviews. They varied in length and details of reporting. [39] . They identified two and four reviews respectively, which were amongst those we 205 also retrieved. Thus, the reasons for exclusion in their case were: review of reviews (overview, rather 206 than a systematic review), no data for extraction, and on the grounds of repetition. 
Description of included reviews 212
Each review included in this meta-review comprised between eight and 13 tools (Table 6, although the number of included studies in some reviews was ambiguous (Table 6 ). The reasons for 218 this ambiguity are twofold. First, the number of studies included in each review is different for each 219 tool, thus making it difficult to aggregate in one number ('number of included studies'). Second, the 220 studies included in each review were found each to have reported one or more studies aimed at 221 evaluating a tool. Thus, a number of included studies of '1' may actually refer to a larger number of 222 studies conducted. 223
The reviews aimed to summarise the available evidence by means of a comprehensive overview 224 (Additional file 5). Three reviews [37, 41, 42] also explicitly aimed at an evaluation of the evidence -225
i.e. to critically evaluate the existing tools, or to identify key components and analyse the reported 226 psychometric properties of tools. Two reviews [21, 37] reported a systematic method for evaluation 227 of the tools. 228
Not all reviews made explicit their assessment of the quality of the studies or risk of bias, or 229 assessment of the scales considered. When this was done, the reviews highlighted the 230 methodological limitations of both studies and scales (Additional file 6). For example, in one review 231
[21] the overall assessment was "generally moderate", with 11 points being the highest score out of 232 the 20 point evaluation scale applied, and only four of the 12 tools examined reaching this score 233 (these were Doloplus-2, ECPA, PACSLAC, PAINAD). The heterogeneity of study designs and/or 234 inconsistencies made aggregation of findings in the reviews difficult and/or methodologically 235 
Quality of included reviews 240
We assessed the quality of the systematic reviews through the use of the AMSTAR questionnaire 241 (original questionnaire adapted to a binary scoring : 1 if item is present, 0 if unclear, absent or not 242 applicable) ( Table 8 ). The mean score was about 4.9, in the range from 1 [43] to 10 [41] . 243
Most (6/8 reviews) presented an a priori design and a comprehensive literature search (Q1; Q3). 244
However, in general, the reporting lacked in detail. For example, as shown in Table 8 , the list of 245 included/excluded studies was provided in only three reviews [22, 41, 42] ; the explicit involvement 246 of two or more independent reviewers (Q2) was reported in only one review [41] ; only three reviews 247
[22, 37, 41] explained the methods used to combine findings (Q9) and only one review seemed to 248
have assessed the likelihood of publication bias [41] . This lack of detail in reporting may be due to 249 restrictions on word limits in publications; we did not contact the authors to obtain data when 250 missing. 251
Reviews' findings -the pain assessment tools 252
In total, 28 pain assessment tools were assessed in the eight reviews; nine tools (Abbey Pain Scale, 253 ADD Protocol, CNPI, DS-DAT, Doloplus-2, NOPPAIN, PACSLAC, PADE, PAINAD) were assessed in five 254 or more reviews; one tool (MOBID) was assessed in three reviews; three tools (Behavior checklist, 255
Observational Pain Behaviour Tool and PATCOA) were assessed in two reviews and the remaining 15 256 tools were assessed in one review each (see Table 7 ; a summary of each provided in Additional file 257
7). 258
It should be noted that there seem to be different versions of PACSLAC: a preliminary 60 items one, 259 then modified to 36 items. There seems to be ambiguity about which version of the tool the data are 260 reported about (a Dutch version -PACSLAC-D was also mentioned [22] ). Similar ambiguity was 261 found in relation to PADE, being unclear which version -or which of its subscales -was studied for 262 psychometric properties. Similarly, the MOBID tool has been studied in two different versions. It is 263 also unclear how much the Abbey Pain Scale had been refined across the studies carried out to 264 evaluate it (including a Japanese version). 265
Description of the tools 266
The reporting of the tools' content and intended use was done differently by different reviews, 267 making it difficult to provide a comprehensive comparative descriptive summary of all the 28 tools. 268
Six of the eight reviews [ From the eight reviews, it appears that most tools (24 out of 28) are observational (Additional file 7), 274 requiring observations by healthcare professionals. However, reviewers' classification of these 275 observational tools varied: FLACC was described as a 'behavioural scale' rather than observational 276
[37]; Abbey Pain Scale, PADE and PAINE were classified by one review [22] as 'caregiver or informant 277 rating scales'; the same review [22] classified the ADD tool as 'interactive'-i.e. an "interactive 278 method" including "a physical and affective needs assessment, a review of the patient's history, and 279 the administration of analgesic medication" [22] . In a number of reviews no specific classification is 280 made. Among the remaining four tools of the 28, one (PPI) relied on patient self-reporting and one 281 (PPQ) was described as relying on caregivers reporting and compared pain experienced currently 282 with pain experienced the previous week. 
scales/ binary scores). 295
Only two out of 28 tools (CNPI, NOPPAIN) appear to be designed explicitly for pain assessment at 296 both rest and during movement -though data about this aspect of the tool's design may be missing 297 for the other tools. For one tool (Doloplus-2) the score was reported to reflect the progression of the 298 pain experienced, rather than the patient's pain experienced at a specific moment in time. 299
Two tools (REPOS and ADD Protocol) combine assessment with guideline for intervention (this is 300 discussed further in the next section). 301 Three reviews [37, 42, 44] explicitly analyse the tools in terms of whether their design apply the AGS 302 
Settings where the tools were studied 308
The tools were studied in a variety of settings and with varied patient populations. The terminology 309 used to describe settings varied, and those which appeared to be in non-acute settings included: 310 long-term-care, nursing homes, dementia care units, psychogeriatric units, rehabilitation facilities, 311 aged care facilities, residential care facilities, long-term care facilities, palliative care but also, 312 geriatric clinics, care homes, residential and skilled care facilities, long-term-care dementia special 313 care units, and a residential dementia care ward (Additional file 8). 314
The terminology to refer to hospital settings also varied, with reference either to patients and/or 315 type of services: e.g. hospital patients in a long-term stay department, psychiatric hospital setting, 316 hospital medical care unit, dementia special care units in hospital, hospital patients and older 317 hospital patients. 318
Tools psychometric data 319
Reliability 320
The reliability of pain assessment scores was measured using inter-rater reliability (agreement 321 between raters), test-retest (extent to which a tool achieves the same result on two or more 322 occasions when the condition is stable) or intra-rater reliability (agreement of the same rater at 323 different time points) and internal consistency (Additional file 9). There were no reliability data 324 available for four of the tools (ECS, Pain assessment scale for use with cognitively impaired adults, 325
Observational Pain Behaviour Tool and Behavior Checklist). Overall, reliability measures were carried 326 out on small samples of patients and raters, so data for all of the tools are limited. Overall, the majority of the tools assessed had moderate to good inter-rater reliability. However, 344
there were limitations in terms of the sample sizes used to evaluate their reliability. 345
Test-retest and intra-rater reliability: Intra-rater reliability was not assessed for the FLACC, Mahoney 346
Pain Scale, PBM, PPI, PAINAD, PATCOA, ECPA, EPCA-2 and the ADD protocol. Evaluations of intra-347 rater reliability included percentage agreement, correlation, kappa, Nygard test-retest and intra-348 class correlations. In terms of inter-rater reliability, the variation in calculations makes direct 349 
Validity 364
The validity of the pain tools was primarily explored using concurrent and/or criterion validity 365 (correlation of the pain scale with other pain scores or a benchmark criterion) and/or discriminant 366 and/or predictive validity (e.g. ability to discriminate, or predict between pain on movement and at 367 rest) (Additional file 9). Some reviews (e.g. [21, 37]) also provided brief insight into the conceptual 368 foundation of the measures and ways content validity was explored (Table 13) . As with measures of 369 reliability, there was considerable variation in how the validity of tools was assessed. Three tools had 370 no validity assessment (the Comfort checklist, the Pain assessment scale for use with cognitively 371 impaired adults and the Observational Pain Behaviour Tool). The Non-Communicative Patient's Pain 372 Assessment Instrument (NOPAIN) tool also had little overall formal validity assessment. 373
Content validity 374
In general, only limited insight was provided into the conceptual foundation of the tools (as opposed 375 to the tool's purpose) (Additional file 10). For the vast majority of tools, their derivation, and thus 376 the implied conceptual basis, lay in literature reviews and/or clinical and/or research experts in pain 377 and older patients with dementia. For other tools, for example, the Abbey Pain Scale, its basis was 378 unclear or, as with the Behaviour Checklist, no information was provided. Two of the measures were 379 adapted from measures originally developed for a different patient group, in particular, young 380 children (Doloplus-2; ECPA). In contrast, the purpose of all the measures was commonly outlined. It 381 is notable that some were developed for particular users (CPAT, for certified nursing assistant care 382 providers; NOPPAIN, for nursing assistants), another for research purposes (DS-DAT) and two as 383 decision support tools (the ADD Protocol and the REPOS). 384
Concurrent and criterion validity 385
Concurrent and criterion validity were measured by either comparing the scores of one tool to 386 another, or comparing one tool's scores with nurse/doctor ratings of pain, or through comparison 387 with self-report (using VAS scales) (Additional file 11). The following is a summary of the 388 comparisons: 389
• CPAT was compared to DS-DAT (rs=22, p=0.076, rs=0.25, p=0.048) 390
• PAINAD compared to the DS-DAT (0.56-0.76) 391
• DS-DAT compared to the Pittsburgh Agitation Scale (0.51) and the Cohen-Mansfield 392 Assessment Inventory (0.25) 393
• Doloplus 2 compared with the PAINAD (0.34) and PACSLAC (0.29-0.38) 394
• REPOS compared to PAINAD (0.61-0.75) 395
• FACS was compared to PBM (0.02-0.41) 396
• PAINE compared with PADE (r=0.65) 397
• PADE compared to CMAI (0.30 -0.42) 398
• nurse/doctor ratings of pain, and the RaPID with self-reports of pain/discomfort. There was no one 411 scale that appeared to be superior to the others (nor applicable as a gold standard), and no 412 consistency in comparisons across the scales. 413
Discriminant validity 414
Discriminant validity was measured by comparing scores before or after a painful event. Several of 415 the reviews reported that tools had discriminant or predictive validity without providing data -this 416 included the reviews of the FACS and PBM. Other scales with a significant difference in scores pre 417 and post interventions/events included the CPAT, CNPI, DS-DAT, PACSLAC, MOBID, Abbey Pain Scale, 418 ADD protocol, and the Behaviour checklist. 419
Construct validity 420
Construct validity was measured by comparing scores to medication use or prescription of 421 medications. The PPQ scores were correlated to pain medication use (0.37-0.55), and patients 422 assessed with the PADE on psychoactive medications had significantly higher scores on the physical 423 and verbal agitation subscales. With the PAINAD there was a significant fall in score after the 424 administration of pain medication, and the EPCA-2 was correlated with the prescription of opioids 425 (0.782) and non-opioids (0.730). 426
Feasibility and clinical utility 427
The feasibility of a tool is "its applicability in daily practice", including aspects such as ease of use 428 and time to administer it, while clinical utility is "the usefulness of the measure for decision making", 429
i.e. to inform further action, such as the administration of analgesics [44] . Data on feasibility and 430 clinical utility of tools were very limited (Additional files 12 and 13). Often data were not available in 431 the reviews, or when data were available, it often pertained to a lack of data in the original studies 432 (e.g. reviewers stating the item was not reported and could therefore not be assessed). More 433 specifically: feasibility data were completely absent for six tools (Comfort Checklist, FLACC, PAINE, 434 PATCOA, PPI, PPQ); clinical utility data were completely or substantially absent for seven tools (ECS, 435 FACS, Mahoney Pain Scale, PAINE, PBM, PPQ, RaPID). For four tools reviewers explicitly noted that 436 claims of feasibility (e.g. time required to administer the tool) were made from the authors of the 437 study without supporting evidence (Abbey Pain Scale, Doloplus-2, PACSLAC, PADE). There were also 438 two instances (PACSLAC and MOBID) of conflicting data on clinical utility and feasibility from the 439 different reviews, possibly due to an ambiguous reference to different versions of the same tool. 440
Specific evaluation for feasibility appears to have been carried out only for three tools -CPAT, 441
Mahoney Pain Scale, and Pain Assessment Scale for Use with Cognitively Impaired Adults; in the first 442 two of these cases the evaluation was done by use of questionnaires. It also appeared that users of 443 the Abbey Pain Scale were asked for feedback in the context of the psychometric testing of the tool. 444
In was unclear whether the ADD Protocol was also assessed for feasibility. 445
Specific evaluation of clinical utility appeared to have been -undertaken for the Pain Assessment 446
Scale for Use with Cognitively Impaired Adults, and possibly for the ADD Protocol and PAINAD. 447
It must be stressed that when reviews assessed or mentioned the feasibility and/or clinical utility of 448 the tools, the two aspects were often confounded (reviewers, authors or users typically drawing 449 conclusions from ease of use or brevity of a scale to its usefulness). With the exception of the ADD Protocol and REPOS, there was no mention of how the tools would 497 inform intervention (e.g. choice of treatment). We found an overall lack of clarity in the descriptions 498 of the ADD Protocol, but it seems that one of its strengths is that it links observation of behaviour 499 with interventions. Similarly, one review suggested that the clinical utility of REPOS potentially 500 resides in its combination with a decision tree to assist in determining interventions after pain 501 assessment [41] . 502
Overall assessment of the tools 503
There seemed to be a general consensus among the reviewers that the current evidence on 504 validation and clinical utility of the tools is insufficient (Additional file 14). The overall conclusion was 505 that there is a need for further psychometric testing of each tool. Two reviews recommended that 506 the focus should be on studying existing scales rather than creating new ones [21, 27], although one 507 review also suggested that there may be a need to revisit the tools' conceptual foundations [37] . Some of the reviews also concluded with recommendations for practice, for example: the use of at 513 least two different pain assessment approaches at the same time in clinical practice and two 514 different tools in research [22] ; the importance of a comprehensive approach to pain assessment 515 beyond the use of tools [37] ; the need to involve social workers in regular holistic multidisciplinary 516 pain assessment (in nursing homes), with training in the use of the scales [42] . 517 Among the tools selected by the reviews as possible best candidates, albeit on limited evidence, 518
were the DS-DAT, Doloplus 2, Mahoney Pain Scale, PACSLAC, PAINAD, Abbey Pain Scale, and ECPA. 519
The ADD protocol was mentioned as an example of a more comprehensive approach for the 520 identification of pain, beyond the use of an assessment tool as "a standardized tool is only one step 521 in a complex diagnostic process" [37] . There was also agreement on recommending that patients 522 with dementia can often reliably verbalise their pain, suggesting therefore that the use of 523 observational scales should be limited to patients who demonstrably cannot reliably verbalise their 524 pain. 525
Discussion
526
The objective of our meta-review was to identify which tools are available to assess pain in adults 527 with dementia, in which settings and patient population they have been used, and evaluate their 528 reliability, validity, feasibility and clinical utility. We found a relatively large number of reviews on 529 this topic and a considerable number of pain assessment tools available for the cognitively impaired 530 population. Of the reviews we evaluated, only one [41] met all of the quality criteria outlined in the 531 AMSTAR checklist, and would be considered a high quality review. The review by Herr et al [37] has 532 an associated website where 17 tools (specifically for use in nursing homes) are listed and 533 commented on in detail [45] . 534
The systematic reviews commonly situated their choice of interventions to review in the context of 535 the challenges associated with assessing pain in patients who were cognitively impaired. Whilst 536 there was recognition that the gold standard for pain assessment was the patient's own assessment, 537 this was unlikely to be possible with this patient population if the person was severely cognitively 538 impaired, thus leading to the use of observational scales. The tools included in these reviews were 539 therefore for the greater part observational, but showed a broad variation of measures and methods 540 of assessing pain in adults with dementia. The foundation and focus of an observational scale is how 541 the pain is manifested or made known such as on the basis on the American Geriatric Society (AGS) 542 Pain indicators [13] . An additional conceptual foundation resided on a differentiation of aspects of 543 pain -such as "the sensory-discriminative and motivational-affective aspects" [46] . Very few tools 544 appeared to have any strong theoretical underpinning to the development. 545
Overall there was no one tool that appeared to be more reliable and valid than the others. There 546 was considerable variation in how reliability and validity of the tools were assessed. The majority of 547 reliability and validity assessments were carried out on small samples in one or two different studies 548 -so the applicability of tools across settings is yet to be evaluated. Similar conclusions can be drawn 549 in relation to the feasibility and clinical utility of the tools. These findings have implications for 550 research, which we briefly discuss over four points: 551
First, given the large number of existing tools identified within our meta-review, it seems 552 inappropriate to develop further tools if on the basis of the same conceptual foundations. Instead, 553 researchers need to either envision new assessment instruments on the basis of different 554 conceptual foundations, or concentrate on extending the psychometric evidence base for the 555 existing tools. There is a need to evaluate the tools on a wider scale, across a variety of patients and 556 clinical settings, using rigorous methods and larger sample sizes. The studies need to ensure that the 557 definitions of cognitive impairment and type of pain that is being assessed are clearly defined, to 558 enable comparisons across populations. While rigorous research is needed, it must be noted that 559 the accuracy of tools is difficult to assess when an objective biological marker or other gold standard 560 criterion is lacking -such as is the case for pain intensity [40, 41, 47] . 561 Second, research should be conducted in clinical practice to assess the feasibility and clinical utility 562 of the tools, and thus their potential for use in everyday clinical practice. Tools may be more useful 563 in detecting relative changes in individual patients than differences between patients [31]. Tools that 564
showed high reliability in research may not display to be highly reliable in routine clinical practice if 565 not administered as intended [48] . Pain assessment tools designed for research purposes, in order to 566 aggregate and compare data across patients, do not necessarily transfer easily and effectively to 567 clinical settings for everyday use. In general it has been suggested that measurement tools 568 developed for the purpose of evaluation of policy making [49, 50] comfort interventions" (p179). Alternatively, the use of the wrong pain assessment tool might 579 reduce the likelihood that pain treatment will be initiated or contribute to acute exacerbations of 580 pain (as could be inferred by data from [43]), or may be found to have no effect on the quality of 581 pain management [52] . 582
Finally, an instrument must be relevant to "the condition, setting and participants in the health 583 interaction, in particular the patient and clinical users" [53] . This includes the notion of user-584 centredness, defined as "the extent to which an instrument faithfully captures both the content of 585 the health care user's views and the form or ways in which their views are expressed" [54] . As a 586 number of the systematic reviews and other literature makes clear, pain is a subjective experience; 587 thus the associated measurement gold standard is the patient's own assessment [44] . However, 588 where the patient is severely cognitively impaired, alternative ways to assess the patient's level of 589 pain must be found. Resort is made to behavioural indicators and groups of cues [55] . Ideally, these 590 aspects would be used to assess expressed pain when the patient is at rest and when moving. over-familiarity may lead to an attenuation of the observer's focus on potential pain clues. 598
However, as Smith [43] commented, one is rarely in 'an ideal situation' where the direct care 599 providers know, and are thus highly familiar, with the care recipient's personal habits and history. 600 into the guidance over who should administer the tools in any of the systematic reviews. To gain 607 insight into this aspect of use and possible additional evidence on a tool's actual use in practice, one 608 would need to examine the original instrument designers' papers and validation studies, rather than 609 rely on a systematic reviewer's observations or summaries. Notwithstanding, it can be 610 recommended that these two aspects of tool use (guidance and actual use) are incorporated into 611 tools reviews and, given this patient group, development of evidence on the actual use of the tools 612 in clinical practice. 613
Overall completeness and applicability of evidence 614
We analysed 23 reviews for data extraction and included data from eight of these. Whilst we could 615 have been more strict in our interpretation of the criteria for a systematic review and exclude a 616 greater number of potentially eligible records before reaching the stage of data extraction, this 617
would not have necessarily restricted the analysis to reviews with higher AMSTAR scores. It would 618 have given us a smaller number of records for data extraction, and while this would have saved us 619 time in the data extraction process, we do not believe that it would have changed the final outcome 620 and the findings. It would also have reduced the number and range of tools assessed. 621
We analysed 28 tools included in eight reviews. However other tools are also available and were 622 included in some of the reviews we excluded because they did not provide psychometric data for 623 extraction. The review by Stolee et al [40] , for example, covers 30 tools, including The Proxy Pain 624
Questionnaire, The Pain Behavior Measure, the 21-Box Scale, and the Pain Thermometer, among 625
others. 626
Furthermore, this meta-review does not cover a new tool recently developed in France by the 627 Doloplus Collective team -ALGO Plus [56] . To our knowledge, the tool has not been included yet 628
(at the time of writing) into a systematic review. 629
Potential biases in the overview process 630
We checked further available data when readily available, such as in supplementary tables online 631
[22] but we did not enquire with the authors to obtain missing data. This may have introduced 632 publication bias. 633
In our assessment of the reliability and validity of the tools, we did not attempt a meta-analysis; we 634 are aware that studies had been counted in various reviews and their results could have been 635 counted more than once. However, we do not believe this to be an issue for our narrative synthesis. 636
Our search did not specifically target reviews reporting on the feasibility or clinical utility of the tools 637 -thus our evidence may be more limited on these aspects than it might have been otherwise. 638
We attempted to minimise bias in the review process by involving a review team with diverse 639 expertise; by having each review assessed independently by at least two members of the team, and 640 the whole team of reviewers involved at every stage of the process; by not excluding reviews on the 641 basis of our assessment of their quality. 642
Conclusions
643
The assessment of pain in patients with dementia is challenging for clinicians, due to some patients' 644 inability to verbalise the nature of their pain. Our review has identified a total of 28 tools that could 645 possibly be used in clinical practice to help with this process; however we cannot at present 646 recommend any particular tool for use in any clinical setting, due to the lack of comprehensive 647 evidence on the reliability, validity, feasibility or clinical utility of any one particular tool. 648
Research should be conducted on the psychometric properties of tools and in clinical practice to 649 assess feasibility, clinical utility and guidance on use of the tools. These are necessary albeit not 650 
667
Screening algorithm (based on inclusion criteria as per Table 1 ). Each decision point has the three option for 668 promoting records to the next stage of the winnowing process: 'yes' (inclusion), 'no' (exclusion), 'maybe'.
669
Depending on the stage of the reviewing process (on title and abstract only, or full text), the latter option may 670 require retrieving the full text, discussion between reviewers, and/or referral to a third reviewer. The definition of criteria for inclusion of potentially relevant reviews follows an adapted SPICE 685 structure (Setting, Population, Intervention, Comparison, method of Evaluation) [16] . All criteria 686 must be met for reviews to be included. 687
Criteria Definitions Setting Reviews pertaining to any setting
Settings are for example acute hospitals, nursing homes, community settings. Patient population Reviews of studies limited to adult dementia patients or adults with cognitive impairment. All stages of dementia in adults will be considered (e.g. mild, severe). Reviews of studies of the assessment of pain and of pain assessment tools. Reviews that include management of pain considered if they also cover assessment of pain. All forms of pain considered (e,g. acute pain, persistent), without distinction on location of pain (e.g. abdominal pain). Reviews of studies of pain assessment included, irrespective of the outcomes of the assessment (e.g. patients being in pain or not). 
Additional criteria
Reviews to be included only if with data and/or assessment of reliability and/or validity and/or clinical utility Inclusion limited to English language Reliability: "the degree to which the measurement is free from measurement error" [58] Validity: "the degree to which the [instrument] measures the constructs(s) it purports to measure" [58] Clinical utility: "the usefulness of the measure for decision making", i.e. to inform further action, such as the administration of analgesics [44]. 
732
assessment we carried out relied on the information reported in the review -we did not contact the authors of the reviews to gather information which was missing or 733 ambiguous in their publication. As a consequence, it may be possible that the authors had performed, for example, a comprehensive literature search for their review, but 734 they did not report this in sufficient detail in their publication. This also caused uncertainty and ambiguity between the No and Can't Answer options, with blurred 735 boundaries between the two. In addition, the AMSTAR questionnaire presents some double-barrelled questions (Q2, Q5, Q7) and we scored the item as present (a score of 736 1) only when both items in the question were answered positively. So, for example, only when both the lists of included and excluded studies were provided (Q5) a score of 737 1 would be awarded to the review. Table AF5 . Summary of reviews methods -criteria for inclusion, method for analysis, and quality of the studies Description of data Overview of the included reviews, with a description of the aims and the methods used for including and analysing the studies, their quality assessment of the studies, and the tools examined. Analysis of the data extracted from the reviews regarding conceptual foundation of each tool and ways content validity was explored. These aspects also pertain to the user-centredness of the tools. 
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Additional files
